Clinical trial
A Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Dapsone for the Treatment of COVID-19 Positive Patients.
NCT04935476 is registered in ClinicalTrials.gov with McGill University Health Centre/Research Institute of the McGill University Health Centre as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Dapsone for the Treatment of COVID-19 Positive Patients.
- Lead sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- November 22, 2021
- Completion date
- July 31, 2022
- Enrollment
- 3,000 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.